SCHEMBL5451659

SCHEMBL5451659

Cc1nocc1C(=O)Nc1sc2c(c1C(N)=O)CCCC2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 8/20 0.65
ALDH1A1 P00352 6/20 0.65
HSD17B10 Q99714 4/20 0.65
KDM4E B2RXH2 3/20 0.65
HPGD P15428 3/20 0.65
L3MBTL1 Q9Y468 3/20 0.65
RAB9A P51151 5/20 0.64
MAPT P10636 5/20 0.64
NPC1 O15118 4/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
LMNA P02545 1/20 0.64
ALOX15 P16050 1/20 0.64
TSHR P16473 1/20 0.64
NPSR1 Q6W5P4 1/20 0.63
GAA P10253 1/20 0.61
CFTR P13569 2/20 0.59
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C19 P33261 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5450662 0.80 ALDH1A1 (0.67) FLT3ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL5453093 0.79 FLT3 (1.00) FLT3ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL5458447 0.79 ALDH1A1 (0.68) FLT3ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL8290390 0.76 FLT3 (0.67) FLT3ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL5463079 0.75 FLT3 (1.00) FLT3ALDH1A1L3MBTL1RAB9AMAPT
SCHEMBL5451249 0.75 RAB9A (0.72) FLT3ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL24490597 0.74 CFTR (1.00) FLT3ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL8288764 0.74 FLT3 (0.78) FLT3ALDH1A1HPGDL3MBTL1RAB9A
SCHEMBL5460003 0.74 FLT3 (0.78) FLT3ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL8289720 0.74 NPC1 (0.73) FLT3ALDH1A1HSD17B10KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1294707-A2 THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2003-03-26 EP claimed
WO-2001098290-A2 THIOPHENE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2001-12-27 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885ALDH1A1 1153/4885HSD17B10 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.